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Abstract
Aims Many heart transplant recipients will develop end-stage renal disease in the post-operative course. The aim of this
study was to identify the long-term incidence of end-stage renal disease, determine its risk factors, and investigate what sub-
sequent therapy was associated with the best survival.
Methods and results A retrospective, single-centre study was performed in all adult heart transplant patients from 1984 to
2016. Risk factors for end-stage renal disease were analysed by means of multivariable regression analysis and survival by
means of Kaplan–Meier. Of 685 heart transplant recipients, 71 were excluded: 64 were under 18 years of age and seven were
re-transplantations. During a median follow-up of 8.6 years, 121 (19.7%) patients developed end-stage renal disease: 22 re-
ceived conservative therapy, 80 were treated with dialysis (46 haemodialysis and 34 peritoneal dialysis), and 19 received a kid-
ney transplant. Development of end-stage renal disease (examined as a time-dependent variable) inferred a hazard ratio of
6.45 (95% conﬁdence interval 4.87–8.54, P < 0.001) for mortality. Tacrolimus-based therapy decreased, and acute kidney in-
jury requiring renal replacement therapy increased the risk for end-stage renal disease development (hazard ratio 0.40, 95%
conﬁdence interval 0.26–0.62, P < 0.001, and hazard ratio 4.18, 95% conﬁdence interval 2.30–7.59, P < 0.001, respectively).
Kidney transplantation was associated with the best median survival compared with dialysis or conservative therapy: 6.4 vs.
2.2 vs. 0.3 years (P < 0.0001), respectively, after end-stage renal disease development.
Conclusions End-stage renal disease is a frequent complication after heart transplant and is associated with poor survival.
Kidney transplantation resulted in the longest survival of patients with end-stage renal disease.
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Introduction
The incidence of chronic kidney disease (CKD) after heart
transplantation (HT) is high with percentages up to 80% re-
ported in some studies.1–6 In a recent study, 19% of the
268 HT recipients developed end-stage renal disease (ESRD)
during a median follow-up of 76 months.7 Risk factors for
the development of CKD after HT include the type of calcine-
urin inhibitor (CNI) used and the presence of
comorbidities.2,3,8,9
Estimating the true incidence of ESRD after HT and its ef-
fect on patient outcome is complicated by the fact that the
deﬁnition of ESRD differed between studies. The deﬁnitions
used in the literature can be as broad as a glomerular ﬁltra-
tion rate (GFR) ≤ 45 mL/min/1.73 m2. Other studies only took
patients who received renal replacement therapy (RRT), ei-
ther dialysis and/or kidney transplantation into consideration.
A small overview of ESRD deﬁnitions used is provided in
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Supporting Information, Table S1. However, according to the
Kidney Disease: Improving Global Outcomes (KDIGO) CKD
guidelines, ESRD is deﬁned as an estimated GFR (eGFR) ≤ 15
mL/min/1.73 m2 or the need for RRT.10 Moreover, HT recipi-
ents with ESRD who were treated conservatively were not in-
cluded. In several studies, the survival of patients who
received a kidney transplant (KT) after HT was compared with
the survival of KT or simultaneous kidney and heart transplant
recipients.11–13 There is only one study that compared dialysis
with KT, demonstrating a survival beneﬁt associated with KT.7
The purpose of this study was to investigate the long-term
incidence of ESRD in a large cohort of HT recipients, deter-
mine risk factors for ESRD, and investigate the effect of ESRD
on survival. Furthermore, the effect of different modalities of
RRT on long-term survival was analysed.
Methods
Patient cohort
In this retrospective study, all adult patients who received an
HT at the Erasmus MC between June 1984 and May 2016
were included. The investigation conforms with the principles
outlined in the Declaration of Helsinki.14 The study was ap-
proved by the Medical Ethical Review Committee of the Eras-
mus MC (MEC-2017-421). When a patient had a re-
transplantation, only the ﬁrst HT was included. When re-
transplanted, the patient was censored at the date of the sec-
ond transplantation.
Pre-operative kidney function
An eGFR of 30 mL/min/1.73 m2 before HT is normally an ab-
solute contraindication for HT. However, this is only the case
when a patient has a decreased kidney function because of a
renal disease. When a patient has a decreased eGFR, we test
for reversibility in order to exclude pre-renal insufﬁciency,
which is frequently encountered in heart failure patients
who are on the waiting list. When reversibility is demon-
strated (by inotropic ± temporary mechanical support), the
patient can still be listed for transplantation. To monitor kid-
ney function before HT, proteinuria is monitored frequently
in order to see whether a patient develops a kidney disease
(such as hypertensive or diabetic nephropathy).
Post-transplantation immunosuppressive
regimen
The immunosuppressive regimen used at our centre was de-
scribed previously.15,16 Until 2000, maintenance immunosup-
pression consisted of ciclosporin (CsA) in combination with
prednisone. If patients experienced rejection, azathioprine
or mycophenolate mofetil was added. After 2000, CsA was re-
placed by tacrolimus as the CNI of choice.
Comorbidity after heart transplantation
Kidney function was classiﬁed according to the 2012 KDIGO
CKD evaluation guidelines and the 2014 National Institute
for Health and Care Excellence guidelines.10,17 ESRD (CKD
Stage 5) was deﬁned as an eGFR ≤ 15 mL/min/1.73 m2 or
when a patient received RRT. RRT was deﬁned as treatment
with dialysis (haemodialysis or peritoneal dialysis) or a KT. Pa-
tients who declined dialysis and/or KT or who were not
deemed ﬁt for dialysis or KT were considered as patients
who received conservative therapy.
Data on kidney function were collected before HT (consid-
ered as baseline), at Month 12 after HT, and then annually.
Estimated GFR was calculated with the CKD-EPI method.18
In addition, demographic and (pre-HT) clinical characteristics
were collected from the electronic patient ﬁles and from
our electronic database. Patients were seen at the Erasmus
MC at least twice a year.
Patients who developed acute on chronic renal failure
within the ﬁrst year but improved (within the ﬁrst post-
transplant year) were not classiﬁed as having ESRD. Rather,
these patients were classiﬁed based on their eGFR at Year 1
and the corresponding CKD stage.
Patients were considered to have diabetes mellitus when
they used any kind of glucose-lowering drug at the time of
HT. Post-transplantation diabetes mellitus was diagnosed
whenever a patient developed the need for any such drug af-
ter HT, and this need persisted for more than 3 months.
Hypertension was deﬁned according to the European Soci-
ety of Cardiology guidelines.19
All patients had a coronary angiogram routinely performed
at Years 1 and 4 after HT. After 4 years, patients underwent a
stress myocardial perfusion imaging annually. When any ab-
normalities were observed, the patient underwent coronary
angiography. Cardiac allograft vasculopathy (CAV) was de-
ﬁned according the 2010 International Society for Heart and
Lung Transplantation (ISHLT) guideline.20
Statistical analysis
The distribution of continuous variables was examined for
normality by means of histograms and skewness coefﬁcients.
Normally distributed continuous variables are presented as
mean ± standard deviation and non-normally distributed var-
iables as median and interquartile range (IQR).
Associations between baseline characteristics and occur-
rence of ESRD and mortality were examined by means of
Cox regression. Patients lost to follow-up were considered
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at risk until the date of last contact, at which time point they
were censored. Moreover, to account for the fact that pa-
tients treated with tacrolimus were unable to reach follow-
up times as long as those of CsA-treated patients, follow-up
was censored at 15 years for all patients for this analysis.
The Cox proportional hazards assumption was assessed by
means of log–log plots. First, univariable Cox models were
used. Subsequently, a multivariable analysis was performed
with variables with a threshold P-value ≤ 0.1.
In the setting of our study, the main event of interest,
ESRD, could have been precluded by death. In that case,
Kaplan–Meier curves overestimate the incidence of the out-
come and Cox regression models may inﬂate the relative dif-
ferences between the groups resulting in biased hazard ratios
(HRs).21 Therefore, in order to further verify the association
between baseline characteristics and ESRD, the analysis of
competing risks was performed with ESRD as event of inter-
est and death as competing event according to a model pro-
posed by Fine and Gray.22 We present subdistribution HRs
from the multivariable Fine and Gray model.
To investigate the risk of death associated with the devel-
opment of ESRD during follow-up, ESRD was entered into an
extended Cox model as a time-dependent variable.
In patients who developed ESRD, univariable Cox models
were used to examine associations between clinical
characteristics and KT. To examine the effect of RRT modali-
ties on survival, the cumulative event rates per RRT modality
were estimated according to the Kaplan–Meier method.
Kaplan–Meier event curves were compared by log-rank tests.
Analyses were performed using statistical software SPSS,
Version 25.0 (SPSS Inc., IBM Company, Chicago, IL), R
Statistical Software, Version 3.5.2 (package ‘cmprsk’), and
GraphPad Prism, Version 5.0a (GraphPad Software, La Jolla,
CA).
Results
From June 1984 to May 2016, 685 HTs were performed in
678 patients. Of these 685 transplantations, 71 were ex-
cluded from the present analysis: 64 patients were aged un-
der 18 years at the time of transplantation and seven were
re-transplantations. The characteristics of the included 614
patients are described in Table 1. Before 2000, 351 patients
were transplanted, and after 2000 (the year when tacrolimus
became the CNI of choice at our centre), 263 were
transplanted. The median follow-up of all patients was 8.6
years (IQR 4.0–14.0).
Table 1 Baseline characteristics of all patients and a comparison between patients with and without ESRD
Parameter
All patients
(n = 614)
HT without ESRD
(n = 493)
HT with ESRD
(n = 121)
Age (years) 51.0 [43.0–56.3] 51.0 [43.0–57.0] 49.0 [42.0–55.0]
Male gender 462 (75) 362 (73) 100 (83)
Caucasian ethnicity 564 (92) 449 (91) 115 (95)
eGFR at HT 63 ± 23 63 ± 23 61 ± 22
CKD stage before HT
CKD Stage 1 78 (13) 65 (13) 13 (11)
CKD Stage 2 244 (40) 195 (40) 49 (40)
CKD Stage 3a 160 (26) 130 (26) 30 (25)
CKD Stage 3b 101 (16) 76 (15) 25 (21)
CKD Stage 4 30 (5) 26 (5) 4 (3)
CKD Stage 5 1 (0.2) 1 (0.2) 0 (0)
Heart failure aetiology
Ischaemic CMP 299 (49) 235 (48) 64 (53)
Non-ischaemic CMP 315 (51) 258 (52) 57 (47)
Diabetes mellitus before HT 41 (7) 34 (7) 7 (6)
MCS before HT 84 (14) 69 (14) 15 (12)
Type of MCS
IABP 45 (7) 32 (6) 13 (11)
LVAD 34 (6) 34 (7) 0 (0)
ECMO 3 (1) 1 (0.2) 2 (2)
BIVAD 1 (0.3) 2 (0.4) 0 (0)
AKI requiring RRT 54 (9) 40 (8) 14 (12)
CsA-based therapy 303 (49) 219 (44) 84 (69)
AKI, acute kidney injury; BIVAD, biventricular assist device; CKD, chronic kidney disease; CMP, cardiomyopathy; CsA, ciclosporin; ECMO,
extracorporeal membrane oxygenation; eGFR, estimated glomerular ﬁltration rate (in mL/min/1.73 m2); ESRD, end-stage renal disease;
HT, heart transplantation; IABP, intra-aortic balloon pump; LVAD, left ventricular assist device; MCS, mechanical support; RRT, renal
replacement therapy.
Categorical variables are presented as %. Normally distributed continuous variables are shown as mean ± standard deviation. Non-
normally distributed continuous variables are shown as a median with [interquartile range].
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End-stage renal disease after heart
transplantation
During follow-up, 121 (19.7%) patients developed ESRD. The
median time between HT and development of ESRD was 7.7
years (IQR 5.0–10.7). ESRD-free survival at 1, 5, and 10 years
of follow-up was 86%, 76%, and 53%, respectively. ESRD
occurred more frequently in male than in female patients
(Table 1). One patient had CKD Stage 5 before HT but did
not develop ESRD after transplantation. This patient had an
eGFR around 70 mL/min/1.73 m2 in the year before HT until
the patient developed severe forward failure and needed
inotropic and mechanical support before HT. The patient
was transplanted urgently. After HT, the eGFR normalized
to 73 mL/min/1.73 m2.
In total, 80 patients were treated with dialysis only: 46
with haemodialysis and 34 with peritoneal dialysis. Nineteen
patients underwent a KT. One of these 19 patients received
a second KT. Only data on the ﬁrst KT were included in the
present analysis. Twenty-two patients were treated conserva-
tively. These patients either declined or were considered too
frail for RRT. In more detail, ﬁve (22.7%) patients had cardiac
comorbidities, 11 (50%) patients had non-cardiac
comorbidities, four (18.2%) patients were not willing to un-
dergo RRT, one (4.5%) patient died before the RRT could be
initiated, and one (4.5%) patient was still being screened for
RRT at the end of follow-up.
Timing of development of end-stage renal disease
after heart transplantation
Of the 121 patients who developed ESRD, 30 developed
ESRD within the ﬁrst 5 years after HT, 58 between 5 and
10 years, and 33 after 10 years. In Table 2, the baseline
characteristics before HT are shown according to the timing
of ESRD development. A higher eGFR before HT was asso-
ciated with a later onset of ESRD. Heart failure aetiology
or the presence of diabetes mellitus before HT was not as-
sociated with the timing of ESRD development. AKI requir-
ing RRT was associated with an increased risk to develop
ESRD (in both the short term and the long term). Causes
of AKI after HT could be divided into one of the following
categories: the haemodynamic insult of the transplant
surgery, pre-renal kidney insufﬁciency due to heart failure,
the introduction of immunosuppression after HT, and other
complications after HT like rejection or infection. Speciﬁc
percentages cannot be given, as a combination of factors
eventually leads to AKI after HT. CsA-based therapy
increased the risk to develop ESRD in the long term [HR
2.36 (1.55–3.60); P < 0.001]. Tacrolimus-based treatment
reduced this risk signiﬁcantly [HR 0.43 (0.28–0.65); P <
0.001].
Post-transplant complications
After HT, 498 (81%) patients had hypertension and 144 (24%)
developed post-transplantation diabetes mellitus. Hyperten-
sion was more frequently present in patients with ESRD than
those who did not develop ESRD (89.3% vs. 79.1%, respec-
tively, P = 0.011). In total, 259 (42%) patients developed
CAV. Patients that developed ESRD had more frequently
CAV than patients without ESRD: 70 (58%) vs. 189 (38%) pa-
tients; P < 0.001.
Survival after heart transplantation in relation to
end-stage renal disease
The overall median long-term survival of the cohort after HT
was 11.7 years (IQR 10.7–12.7). The extended Cox regression
analysis with ESRD entered as a time-dependent variable
demonstrated an HR of 6.45 (95% CI 4.87–8.54, P < 0.001)
for mortality when corrected for age, eGFR at HT, heart fail-
ure aetiology, CsA-based therapy and AKI requiring RRT.
Kidney after heart transplantation
In total, 19 patients received a KT. Five patients received a
kidney from a deceased donor and 14 patients from a living
donor. Of these 14 living donors, seven were related and
seven were unrelated donors. Four patients received a pre-
emptive KT, and 15 were treated with dialysis ﬁrst. In Table 3,
the baseline characteristics of these 19 patients are pre-
sented. The median time between HT and ESRD was shorter
in patients who received a KT compared with patients who
did not (7.1 vs. 8.7 years, P < 0.0001). The median time be-
tween HT and KT was 8.0 years (IQR 4.8–12.1). The median
time between the development of ESRD and KT was 1.5 years
(IQR 0.7–2.7).
Figure 1A depicts the survival of patients who underwent a
KT compared with patients who did not from the time of
ESRD diagnosis. The survival of patients with ESRD who re-
ceived a KT was signiﬁcantly better than patients who did
not (P < 0.0001). When the group of patients who did not re-
ceive a KT was divided into a conservative and a dialysis
group, the same pattern was observed: KT resulted in the
best survival [median 6.4 years (IQR 4.7–8.2)], followed by di-
alysis [median 2.2 years (IQR 1.7–2.7)] and conservative ther-
apy [median 0.3 years (IQR 0.2–0.4)]; P < 0.0001 (Figure 1B).
Patients who received a KT from a living donor had a better
survival compared with those who received a KT from a de-
ceased donor (P = 0.02; Supporting Information, Figure S1A).
Among recipients of a living donor KT, a living-related
donor resulted in a better survival than a living-unrelated
donor (P = 0.02; Supporting Information, Figure S1B).
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Predictors for end-stage renal disease and
mortality
The Cox proportional hazard assumption was met for all var-
iables entered into the multivariable model. In Cox regression
analysis, AKI requiring RRT gave a signiﬁcantly higher risk for
ESRD [HR 4.18 (2.30–7.59, P < 0.001)], while tacrolimus-
based therapy decreased the risk to develop ESRD [HR 0.40
(0.26–0.62, P < 0.001)]. Male gender and eGFR at HT were
not associated with a higher risk of ESRD. The competing risk
analysis (Fine and Gray model) did not alter these associa-
tions (Table 4). For mortality, age gave an increased risk of
mortality of 1.02 (1.00–1.04, P = 0.002) per year (Table 5).
Ischaemic heart failure before HT was associated with an in-
creased risk of mortality after HT of 1.36 (1.04–1.80, P =
0.02). Furthermore, AKI requiring RRT gave an increased risk
for mortality after HT: HR 2.79 (1.68–4.61, P < 0.001), while
tacrolimus-based therapy decreased the risk (in comparison
with CsA): [HR 0.35 (0.26–0.48, P < 0.001)]. Estimated GFR
at HT was not a predictor of mortality after HT.
Discussion
The present study demonstrates that ESRD is a frequent com-
plication of HT and is associated with a more than six-fold
Table 3 Characteristics of heart transplant patients who received a KT vs. those who did not
Parameter All ESRD patients (n = 121) KT (n = 19) No KT (n = 102) Hazard ratio P-value
Age (years) 49.0 [42.0–55.0] 45.0 [41.0–52.0] 50.0 [44.8–55.0] 1.01 (0.95–1.08) 0.73
Male gender 100 (83) 17 (89) 83 (81) 1.63 (0.37–7.20) 0.52
Caucasian ethnicity 115 (95) 17 (89) 98 (96) 0.26 (0.05–1.28) 0.10
eGFR at HT 61 ± 22 59 ± 23 61 ± 22 0.98 (0.96–1.01) 0.21
CKD stage before HT 1.41 (0.91–2.19) 0.12
CKD Stage 1 13 (11) 3 (16) 10 (10) 1.00a
CKD Stage 2 49 (40) 5 (26) 44 (43) 0.50 (0.11–2.37) 0.38
CKD Stage 3a 30 (25) 4 (21) 26 (25) 2.43 (0.50–11.80) 0.27
CKD Stage 3b 25 (21) 7 (37) 18 (18) 1.64 (0.40–6.74) 0.49
CKD Stage 4 4 (3) 0 (0) 4 (4) — —
CKD Stage 5 0 (0) 0 (0) 0 (0) — —
Time from HT to ESRD (years) 7.7 [5.0–10.7] 5.9 [2.3–8.9] 7.9 [5.8–10.9] 0.68 (0.56–0.83) <0.0001
Heart failure aetiology 0.84 (0.33–2.15) 0.72
Ischaemic CMP 64 (53) 10 (53) 54 (53)
Non-ischaemic CMP 57 (47) 9 (47) 48 (47)
Diabetes mellitus before HT 7 (6) 2 (11) 5 (5) 1.14 (0.25–5.10) 0.87
MCS before HT 15 (12) 3 (16) 12 (12) 1.11 (0.30–4.08) 0.87
AKI requiring RRT 14 (12) 5 (26) 9 (9) 12.71 (2.88–56.13) 0.001
AKI, acute kidney injury; CKD, chronic kidney disease; CMP, cardiomyopathy; eGFR, estimated glomerular ﬁltration rate (in mL/min/1.73
m2); ESRD, end-stage renal disease; HT, heart transplantation; KT, kidney transplantation; MCS, mechanical support; RRT, renal replace-
ment therapy.
Categorical variables are presented as %. Normally distributed continuous variables are shown as mean ± standard deviation. Non-nor-
mally distributed continuous variables are shown as a median with [interquartile range]. Results of univariable Cox regression analysis
are shown with hazard ratios (CIs).
aReference.
Figure 1 (A) Survival curve after the development of end-stage renal disease of patients receiving a kidney transplant (KT) vs. no KT. (B) Survival curve
after development of end-stage renal disease of patients receiving a KT vs. dialysis vs. conservative therapy.
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increased risk of death compared with patients who do not
develop ESRD. This is in line with other studies.2,3 In the mul-
tivariable analysis, CsA-based therapy (in comparison with
tacrolimus-based therapy) and AKI requiring RRT were inde-
pendent risk factors for ESRD development. Patients who re-
ceived a kidney-after-heart transplant had a better survival
compared with ESRD patients who were treated with dialysis
or conservative therapy. Living donor KT resulted in a better
survival compared with deceased donor KT.
The long-term incidence of ESRD after HT in this study
(19.7%) is comparable with the incidence found by Grupper
et al.7 who reported an incidence of 19% in a cohort of 268
patients. The 2017 ISHLT Registry Report reports an incidence
of severe renal dysfunction (deﬁned as the development of a
serum creatinine ≥221 μmol/L, chronic dialysis, or renal
transplant within 10 years) of 29.2% among 8261 HT recipi-
ents of whom 10.5% received chronic dialysis or renal trans-
plant.23 In comparison with Grupper et al., we used the
KDIGO criteria to deﬁne ESRD, which encompasses a wider
range of renal insufﬁciency. Furthermore, our median
follow-up time was signiﬁcantly longer (103 vs. 76 months,
respectively). The median time between HT and the develop-
ment ESRD in our study was 92 months (IQR 59–128), which
was longer compared with other studies. Both Grupper et al.
and Cassuto et al.7,13 noticed a shorter onset of ESRD after HT
(83 and 65 months, respectively). This implies that the renal
function of our patients was better and longer preserved in
comparison with other studies. As renal failure remains one
of the Achilles’ heels of the survival after HT, a nephrologist
has participated in the HT team since the start of our
programme. Monitoring proteinuria is now an integral part
of our post-HT surveillance and is recommended by both
KDIGO and National Institute for Health and Care Excellence
guidelines.10,17
Ciclosporin was an independent predictor of ESRD in our
study, conforming the results of earlier studies.1,2 In addition
to reducing the incidence of acute rejection, this is an impor-
tant advantage of tacrolimus over CsA. Furthermore, AKI re-
quiring RRT was a predictor for both ESRD and mortality.
This is in line with studies of Fortrie et al. and Ojo et al..2,15
The fact that we added a competing risk analysis to our study
strengthens the result found in this study.
The exact reason why patients develop ESRD after trans-
plant is unknown. Many factors play a role in the deteriora-
tion of kidney function after transplantation. AKI is one of
the factors leading to ESRD in HT recipients.15 In a recent re-
view by Fortrie et al.24 on the relationship between AKI
and ESRD, this is further discussed. Normally, the kidney is
capable to repair damaged tissue and has enough
residual function. In patients with pre-existing comorbidities
(i.e. hypertension or diabetes mellitus), this capacity is dimin-
ished. When these patients develop AKI, inﬂammatory cyto-
kines are activated, leading to hyperﬁltration. This can
promote glomerulosclerosis and tubulointerstitial ﬁbrosis
and ﬁnally ESRD.24 Furthermore, the use of CNIs (CsA and ta-
crolimus) has deleterious effects on the kidney function as
demonstrated in this manuscript. Further research is needed
to understand the causes of ESRD in HT patients in order to
develop therapeutic or even preventive options for this pa-
tient group.
Table 4 Risk prediction for end-stage renal disease
Covariate
Cox model Fine and Gray model
HR 95% CI P-value SHR 95% CI P-value
Male gender 1.59 0.93–2.69 0.08 1.67 0.99–2.81 0.05
eGFR at HT 0.99 0.98–1.00 0.08 0.99 0.98–1.00 0.11
Tac-based therapy 0.40 0.26–0.62 <0.001 0.54 0.36–0.83 0.004
AKI requiring RRT 4.18 2.30–7.59 <0.001 2.48 1.33–4.62 0.004
AKI, acute kidney injury; CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate (in mL/min/1.73 m2); HR, hazard ratio; HT, heart
transplantation; RRT, renal replacement therapy; SHR, subdistribution hazard ratio; Tac, tacrolimus.
HRs from multivariable Cox model and SHRs from multivariable Fine and Gray model for mortality.
Table 5 Risk prediction for mortality
Covariate
Cox model Fine and Gray model
HR 95% CI P-value SHR 95% CI P-value
Age (years) 1.02 1.00–1.04 0.002 1.03 1.01–1.04 <0.001
eGFR at HT 1.00 0.99–1.00 0.67 1.00 0.99–1.01 0.39
Ischaemic CMP 1.36 1.04–1.80 0.02 1.33 1.01–1.74 0.04
Tac-based therapy 0.35 0.26–0.48 <0.001 0.39 0.28–0.52 <0.001
AKI requiring RRT 2.79 1.68–4.61 <0.001 2.13 1.24–3.62 0.005
AKI, acute kidney injury; CI, conﬁdence interval; CMP, cardiomyopathy; eGFR, estimated glomerular ﬁltration rate (in mL/min/1.73 m2); HR,
hazard ratio; HT, heart transplantation; RRT, renal replacement therapy; SHR, subdistribution hazard ratio; Tac, tacrolimus.
HRs from multivariable Cox model and SHRs from multivariable Fine and Gray model for mortality.
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One question that may arise in the light of our results is
whether combined kidney–HT (KHT) is an option for patients
with compromised kidney function (or even renal failure) and
whether this will result in less ESRD in the long term. Several
studies (both single-centre and national) have demonstrated
a good survival after KHT.25–28 In some studies using the
United Network for Organ Sharing database, there was even
a survival beneﬁt for patients undergoing combined KHT in
comparison with HT alone.26,27 Even though these studies
suggest a beneﬁt of combined KHT (although all studies have
a maximum follow-up of around 6 years), this type of trans-
plant is not performed in the Netherlands due to the short-
age of suitable donors.
This study has several limitations. First of all, it is a single-
centre study with a low number of KT after HT. Second, bet-
ter survival in patients treated with KT may be inﬂuenced by
selection bias. Patients who develop ESRD early are usually
less frail compared with patients who develop ESRD longer
after HT (although not measured and described). This selec-
tion bias is something present in daily practice, where the
best patients are considered suitable candidates for KT.
Third, the association between the risk of ESRD and CsA or
tacrolimus exposure was not analysed in this study. Patients
with a high CNI exposure may have had an increased risk to
develop ESRD as a result of the drugs’ nephrotoxicity. How-
ever, in clinical practice, in patients with an impaired renal
function, the CNI dose is often decreased, which could result
in the paradoxical ﬁnding that HT recipients with the worst
renal function actually have the lowest exposure to CNI, sug-
gesting that these drugs are nephroprotective. Fourth, kid-
ney biopsies are not routinely performed in our centre.
However, all patients with CKD following HT are seen by a
nephrologist to aid in diagnosing the cause of the renal in-
sufﬁciency and help limit the deterioration of the renal
function.
In conclusion, ESRD is a frequently occurring long-term
complication of HT. Patients who develop ESRD have a
worse survival than patients who do not develop ESRD.
CsA-based therapy and AKI requiring RRT were independent
risk factors for the development of ESRD. When patients
developed ESRD, KT, preferably from a living donor, gave
a better survival than dialysis or conservative therapy.
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